2 unknown, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Recruiting 1 |
Follow Di Wu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma Camrelizumab, Anlotinib, nab-Paclitaxel - Melanoma | Phase 2 | Unknown | Di Wu | 66 | 2021-07-15 | 2021-08-03 |
| Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma SHR-1210+Apatinib - Acral Melanoma | Phase 2 | Recruiting | Di Wu | 40 | 2021-03-01 | 2021-05-26 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Unknown | Di Wu | 25 | 2019-07-19 | 2019-07-10 |
Histiocytoma, Malignant Fibrous (1) · Melanoma (1) · Sarcoma (1)
anlotinib (2) · 130-nm albumin-bound paclitaxel (1) · Biopsy, Needle (1) · Blood Specimen Collection (1) · Phlebotomy (1) · camrelizumab (1) · toripalimab (1)
China (3)